Marketing application submissions are the culmination of years of research and the final hurdle before a product makes it to market.
| This week's FierceBiotech is brought to you by Rho.
Trouble viewing? Click here. |
| Dear E, Marketing application submissions, including NDAs, BLAs, and MAAs, are the culmination of years of research and the final hurdle before your product makes it to market. At Rho, our experts are passionate about developing high-quality marketing applications to help our clients accelerate their time to market, maximize research investments, and bring the benefit of new treatments to patients sooner. Using our collaborative, cross-functional base of knowledge, our experts have compiled key points on regulatory strategy, data integration and readiness, plus electronic publishing that can help ensure a smooth marketing application submission. Download this article to learn about: Early planning and preparation ideas Details regarding leveraging the IND in creation of the NDA How to start with the end in mind when it comes to data Considerations to make sure the product is approvable Suggestions for creating a target product profile Preparation for your End of Phase 2 (EOP2) meeting Creating and maintaining a living clinical database |
|
| If you no longer wish to receive communications from Rho, please opt out here.
Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.
You are currently subscribed as [email protected].
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
